SG11201607894RA - S1p modulator immediate release dosage regimen - Google Patents

S1p modulator immediate release dosage regimen

Info

Publication number
SG11201607894RA
SG11201607894RA SG11201607894RA SG11201607894RA SG11201607894RA SG 11201607894R A SG11201607894R A SG 11201607894RA SG 11201607894R A SG11201607894R A SG 11201607894RA SG 11201607894R A SG11201607894R A SG 11201607894RA SG 11201607894R A SG11201607894R A SG 11201607894RA
Authority
SG
Singapore
Prior art keywords
modulator
immediate release
dosage regimen
release dosage
regimen
Prior art date
Application number
SG11201607894RA
Inventor
Eric Legangneux
Erik Wallstroem
Philippe Michael Rene Bouillot
Emeric Reynaud
Frank Dahlke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201607894R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201607894RA publication Critical patent/SG11201607894RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
SG11201607894RA 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen SG11201607894RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (1)

Publication Number Publication Date
SG11201607894RA true SG11201607894RA (en) 2016-10-28

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607894RA SG11201607894RA (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Country Status (16)

Country Link
US (3) US20170027907A1 (en)
EP (3) EP3129020A1 (en)
JP (1) JP6674903B2 (en)
KR (2) KR20220156981A (en)
CN (2) CN116650467A (en)
AU (2) AU2015246036A1 (en)
CA (1) CA2943598C (en)
CL (1) CL2016002562A1 (en)
IL (2) IL305337A (en)
MX (1) MX2016013245A (en)
PH (1) PH12016501965A1 (en)
RU (2) RU2020107732A (en)
SG (1) SG11201607894RA (en)
TW (1) TW201622721A (en)
WO (1) WO2015155709A1 (en)
ZA (1) ZA201606519B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943598C (en) * 2014-04-10 2023-03-07 Novartis Ag S1p modulator immediate release dosage regimen
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US20200306222A1 (en) * 2017-09-29 2020-10-01 Novartis Ag Dosing Regimen of Siponimod
AU2018341154A1 (en) * 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
MA52424A (en) * 2018-03-01 2021-01-06 Astrazeneca Ab PHARMACEUTICAL COMPOSITIONS CONTAINING (2S) - ((1S) -1-CYANO-2- [4- (3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-YL) PHENYL] ETHYL) -1,4-OXAZEPANE-2-CARBOXAMIDE
CN109908095A (en) * 2019-04-08 2019-06-21 肇庆学院 A kind of Xi Nimode tablet and preparation method
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2676953T3 (en) * 2008-12-18 2017-07-03 Novartis Ag Hemifumarate salt of 1- [4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl] -acetidine-3-carboxylic acid for use in the treatment of lymphocyte-mediated diseases
DK3453387T3 (en) * 2008-12-22 2020-08-10 Novartis Ag DOSAGE PLAN FOR AN S1P RECEPTOR AGONIST
PT2379069E (en) * 2008-12-22 2015-07-03 Novartis Ag Dosage regimen of an s1p receptor agonist
AU2010300919A1 (en) * 2009-09-29 2012-03-22 Novartis Ag Dosage regimen of an S1P receptor modulator
HUE045612T2 (en) * 2011-01-07 2020-01-28 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
KR20140084041A (en) * 2011-10-21 2014-07-04 노파르티스 아게 Dosage regimen for an s1p receptor modulator or agonist
CA2943598C (en) * 2014-04-10 2023-03-07 Novartis Ag S1p modulator immediate release dosage regimen

Also Published As

Publication number Publication date
US20190054065A1 (en) 2019-02-21
JP6674903B2 (en) 2020-04-01
JP2017510607A (en) 2017-04-13
RU2016143979A3 (en) 2018-11-12
IL305337A (en) 2023-10-01
CA2943598A1 (en) 2015-10-15
CN116650467A (en) 2023-08-29
TW201622721A (en) 2016-07-01
CA2943598C (en) 2023-03-07
AU2020203107B2 (en) 2021-10-21
ZA201606519B (en) 2017-11-29
EP3129020A1 (en) 2017-02-15
PH12016501965A1 (en) 2017-01-09
EP4074312A1 (en) 2022-10-19
RU2020107732A (en) 2020-03-30
MX2016013245A (en) 2017-01-16
AU2020203107A1 (en) 2020-05-28
RU2016143979A (en) 2018-05-14
AU2015246036A1 (en) 2016-10-13
KR20220156981A (en) 2022-11-28
KR20160141841A (en) 2016-12-09
WO2015155709A1 (en) 2015-10-15
US20220016076A1 (en) 2022-01-20
IL247986A0 (en) 2016-11-30
CL2016002562A1 (en) 2017-07-28
EP3831378A1 (en) 2021-06-09
US20170027907A1 (en) 2017-02-02
CN106456552A (en) 2017-02-22
RU2715734C2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
IL270954A (en) Pharmaceutical compounds
GB201404922D0 (en) Pharmaceutical compounds
IL247986A0 (en) S1p modulator immediate release dosage regimen
PT3022458T (en) Brake disc-hub connection
HUE043290T2 (en) Dispensing capsule
HK1215385A1 (en) Modified release coated capsules
GB201416513D0 (en) Pharmaceutical compounds
IL247084B (en) Fgh-18 dosage regimen
GB201412955D0 (en) Supramolecular capsules
GB201417707D0 (en) Pharmaceutical compounds
GB201418710D0 (en) Dosage regimen
EP3011948A4 (en) Radiopharmaceutical distribution device
PL3215437T3 (en) Dosage device
SI3145499T1 (en) Modified release coated capsules
HRP20181756T1 (en) Treatment regimen for tiacumicin compound
GB2531773B (en) Medicine pack
GB201418708D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen
GB201508022D0 (en) Pharmaceutical compounds
AU362816S (en) Capsule
GB201416968D0 (en) Pharmaceutical compounds
GB201416969D0 (en) Pharmaceutical compounds
GB201416627D0 (en) Pharmaceutical compounds
GB201416625D0 (en) Pharmaceutical compounds